Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) EBIT: 2021-2024

Historic EBIT for Immunocore Holdings (IMCR) over the last 4 years, with Dec 2024 value amounting to -$70.5 million.

  • Immunocore Holdings' EBIT rose 15.66% to -$7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$45.1 million, marking a year-over-year increase of 33.72%. This contributed to the annual value of -$70.5 million for FY2024, which is 18.13% down from last year.
  • Immunocore Holdings' EBIT amounted to -$70.5 million in FY2024, which was down 18.13% from -$59.6 million recorded in FY2023.
  • In the past 5 years, Immunocore Holdings' EBIT ranged from a high of -$51.7 million in FY2022 and a low of -$174.6 million during FY2021.
  • Its 3-year average for EBIT is -$60.6 million, with a median of -$59.6 million in 2023.
  • Its EBIT has fluctuated over the past 5 years, first spiked by 70.38% in 2022, then dropped by 18.13% in 2024.
  • Yearly analysis of 4 years shows Immunocore Holdings' EBIT stood at -$174.6 million in 2021, then surged by 70.38% to -$51.7 million in 2022, then declined by 15.36% to -$59.6 million in 2023, then fell by 18.13% to -$70.5 million in 2024.